InBody Co.,Ltd (KOSDAQ:041830)
28,700
-50 (-0.17%)
Sep 19, 2025, 3:30 PM KST
InBody Co.,Ltd Revenue
InBody Co.,Ltd had revenue of 56.17B KRW in the quarter ending June 30, 2025, with 11.80% growth. This brings the company's revenue in the last twelve months to 217.55B, up 17.38% year-over-year. In the year 2024, InBody Co.,Ltd had annual revenue of 204.46B with 20.03% growth.
Revenue (ttm)
217.55B
Revenue Growth
+17.38%
P/S Ratio
1.61
Revenue / Employee
636.10M
Employees
342
Market Cap
349.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 204.46B | 34.11B | 20.03% |
Dec 31, 2023 | 170.35B | 10.35B | 6.47% |
Dec 31, 2022 | 160.00B | 22.17B | 16.08% |
Dec 31, 2021 | 137.84B | 30.71B | 28.67% |
Dec 31, 2020 | 107.12B | -9.94B | -8.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |